The US FDA has approved lenacapvir, sold under the brand name Yeztugo, as the first preventive treatment against HIV. It is a ...

The global flow cytometry market revenue was around US$ 4.7 billion in 2021 and is estimated to reach US$ 11.6 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.3% during the ...

an official aware of the matter said. The decision to shift to NAT has already been taken by the regulator, the Drug Controller General of India (DCGI), and the matter was discussed at the Drugs ...

Avoidable deaths are on the rise as Nigeria’s blood banks fail to deliver blood to patients requiring transfusion to survive.

The symptoms Loza describes align with those recognised by the World Health Organization (WHO) as signs of female genital schistosomiasis (FGS). In the first instalment, we examined what FGS is and ...

The target population was composed of HIV-positive patients registered at an outpatient care ... 6-8 with similar goals and which used the same tool (CEAT-VIH) to investigate drug therapy adherence in ...

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...